Published in Br J Ophthalmol on May 01, 1986
Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. Br J Ophthalmol (2006) 0.93
EOG as a monitor of desferrioxamine retinal toxicity. Doc Ophthalmol (2004) 0.87
Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. J Clin Pharm Ther (2010) 0.86
Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress. J Inorg Biochem (2011) 0.81
Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol (2014) 0.80
Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature. Biomed Res Int (2015) 0.79
Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep (2014) 0.79
Retinal abnormalities in β-thalassemia major. Surv Ophthalmol (2015) 0.77
β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol (2016) 0.75
Contrast sensitivity in patients with Beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxamine. Open Ophthalmol J (2010) 0.75
Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity. Digit J Ophthalmol (2017) 0.75
[On iron-containing growth factors, sideramines, and their antagonists, the iron-containing antibiotics, sideromycins]. Experientia (1960) 2.86
Treatment of experimental siderosis bulbi, vitreous hemorrhage, and corneal blood staining with deferoxamine. Arch Ophthalmol (1966) 2.01
Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci (1978) 1.66
Ocular toxicity of high-dose intravenous desferrioxamine. Lancet (1983) 1.63
Retinal detachment in the cat: the pigment epithelial-photoreceptor interface. Invest Ophthalmol Vis Sci (1983) 1.33
Elastic and precursor fibres in the normal human eye. Exp Eye Res (1983) 1.19
The effects of iodate and iodoacetate on the retinal adhesion. Invest Ophthalmol Vis Sci (1980) 1.06
The pigment epithelium of the monkey. Topographic study by scanning and transmission electron microscopy. Arch Ophthalmol (1976) 0.96
Copper metabolism in retinitis pigmentosa patients. Br J Ophthalmol (1981) 0.96
THE EOG IN CHLOROQUINE AND OTHER RETINOPATHIES. Arch Ophthalmol (1963) 0.96
Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus (1979) 0.94
Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol (1999) 1.82
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol (1997) 1.75
Exposure of primary orbital implants in postenucleation retinoblastoma patients. Ophthalmology (2000) 1.70
Intraocular malignant melanomas presenting with orbital inflammation. Eye (Lond) (1993) 1.66
Ocular toxicity of high-dose intravenous desferrioxamine. Lancet (1983) 1.63
Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res (1996) 1.57
Retinal and epiretinal glia--an immunohistochemical study. Br J Ophthalmol (1984) 1.54
Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol (1994) 1.52
Immunological investigations in uveitis. Trans Ophthalmol Soc U K (1976) 1.50
Genetic counselling in retinoblastoma: importance of ocular fundus examination of first degree relatives and linkage analysis. Br J Ophthalmol (1991) 1.50
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol (2002) 1.49
Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol (1997) 1.47
Five cases of coexistent primary ocular and cutaneous melanoma. Arch Dermatol (1993) 1.45
Pathology of practolol-induced ocular toxicity. Br J Ophthalmol (1976) 1.39
Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology (1999) 1.35
Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol (2009) 1.35
Characterisation of ocular melanoma with cutaneous melanoma antibodies. Br J Ophthalmol (1987) 1.35
Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol (1996) 1.35
The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer (1995) 1.29
Immunological studies in keratoconus. Trans Ophthalmol Soc U K (1976) 1.28
Microvessel count predicts survival in uveal melanoma. Cancer Res (1996) 1.27
Choroidal hemangiomas: visual and anatomic results of treatment by photocoagulation or radiation therapy. Ophthalmology (1997) 1.25
Improved external beam radiotherapy for the treatment of retinoblastoma. Br J Radiol (1987) 1.22
The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol (2008) 1.22
Pathogenesis of Mooren's ulcer: some new concepts. Br J Ophthalmol (1984) 1.21
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer (2003) 1.16
Clinical, biochemical, and immunoelectrophoretic study of subretinal fluid. Br J Ophthalmol (1971) 1.14
Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol (1997) 1.14
Ectopic intracranial retinoblastoma in childhood. Br J Ophthalmol (1985) 1.14
Tumors of the anterior uvea. I. Metastasizing malignant melanoma of the iris. Arch Ophthalmol (1980) 1.13
Postenucleation orbital radiotherapy for the treatment of malignant melanoma of the choroid with extrascleral extension. Br J Ophthalmol (1990) 1.10
Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol (1994) 1.09
Impression cytology of conjunctival melanosis and melanoma. Br J Ophthalmol (1992) 1.08
Application of intragenic DNA probes in prenatal screening for retinoblastoma gene carriers in the United Kingdom. Arch Dis Child (1990) 1.07
Epiretinal membranes in vitro. Trans Ophthalmol Soc U K (1983) 1.07
Autoimmunity and the retina. II. Raised serum IgM levels in retinitis pigmentosa. Br J Ophthalmol (1973) 1.07
Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments. Br J Ophthalmol (1987) 1.06
Multifocal amelanotic conjunctival melanoma and acquired melanosis sine pigmento. Br J Ophthalmol (1992) 1.06
Ring melanoma--a rare cause of refractory glaucoma. Br J Ophthalmol (1999) 1.06
Pseudoelastic nature of pterygium. Br J Ophthalmol (1970) 1.05
Malignant melanomas of the conjunctiva, nasal cavity, and paranasal sinuses. Am J Ophthalmol (1989) 1.05
External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol (1995) 1.05
The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs (1997) 1.03
Autoimmunity and the retina. I. Antigenic specificity of photoreceptor cells. Br J Ophthalmol (1970) 1.02
Immunological studies in retinitis pigmentosa associated with retinal vascular leakage. Br J Ophthalmol (1978) 1.02
Uptake of 99mTc labelled (Fab')2 fragments of monoclonal antibody 225.28S by a benign ocular naevus. Eur J Nucl Med (1988) 1.02
Retinoblastoma in Great Britain 1963-2002. Br J Ophthalmol (2008) 1.01
Immunopathology of the lens. I. Humoral and cellular immune responses to heterologous lens antigens and their roles in ocular inflammation. Br J Ophthalmol (1977) 1.01
Experimental immune retinitis: induction by isolated photoreceptors. Mod Probl Ophthalmol (1976) 1.00
Autoimmune reactions in uveal melanoma. Br J Ophthalmol (1971) 0.99
Estrogen and progesterone receptor analysis in ocular melanomas. Ophthalmology (1995) 0.97
Structural basis of contraction in vitreal fibrous membranes. Br J Ophthalmol (1981) 0.96
Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol (2002) 0.96
Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet (1995) 0.96
Oestrogen receptors in conjunctival malignant melanoma: immunocytochemical study using formalin fixed paraffin wax sections. J Clin Pathol (1991) 0.95
c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol (1999) 0.95
Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond) (1998) 0.94
Formation of stable crystalline enzyme-substrate intermediates at sub-zero temperatures. Nature (1976) 0.93
Immunoelectrophoretic analysis of subretinal fluid and its diagnostic significance. Trans Ophthalmol Soc U K (1975) 0.93
Immunopathology of the lens. III. Humoral and cellular immune responses to autologous lens antigens and their roles in ocular inflammation. Br J Ophthalmol (1977) 0.93
Nasal and orbital recurrence of conjunctival melanoma 21 years after exenteration. Br J Ophthalmol (1992) 0.92
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer (1999) 0.92
Microfilaments in the cells of the human trabecular meshwork. Br J Ophthalmol (1979) 0.92
Antifreeze glycoproteins from the blood of an antarctic fish. The structure of the proline-containing glycopeptides. J Biol Chem (1978) 0.91
Premalignant melanosis of the conjunctiva and the cornea in xeroderma pigmentosum. Br J Ophthalmol (1992) 0.90
Immunopathology of the lens. II. Humoral and cellular immune responses to homologous lens antigens and their roles in ocular inflammation. Br J Ophthalmol (1977) 0.89
Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. J Clin Immunol (1998) 0.89
Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy. Br J Ophthalmol (2010) 0.89
Are most intraocular "leiomyomas" really melanocytic lesions? Ophthalmology (1994) 0.89
Tumours of the anterior uvea. III. Oxytalan fibres in the differential diagnosis of leiomyoma and malignant melanoma of the iris. Br J Ophthalmol (1980) 0.88
Malignant melanoma of the eyelid and conjunctiva. Aust N Z J Ophthalmol (1986) 0.87
Antifreeze glycoproteins from an Antarctic fish. Quasi-elastic light scattering studies of the hydrodynamic conformations of antifreeze glycoproteins. J Biol Chem (1975) 0.87
New concepts in the control of ocular inflammation. Trans Ophthalmol Soc U K (1985) 0.87
Contractile protein antigens in the cells of malignant melanoma of the choroid and their diagnostic significance. Br J Ophthalmol (1978) 0.87
Primary orbital melanoma masquerading as vascular anomalies. Eye (Lond) (2002) 0.87
Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol (2003) 0.86
Scrolls of Descemet's membrane as unusual giant nodules on the posterior cornea: histochemical and ultrastructural findings. Br J Ophthalmol (1986) 0.86
Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res (2001) 0.86
Antigenic specificity of retinal pigment epithelium and non-immunological involvement in retinal dystrophy. Nature (1974) 0.86
The prognostic significance of c-myc oncogene expression in uveal melanoma. Melanoma Res (1998) 0.86
Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor? Br J Ophthalmol (2006) 0.86
Effect of temperature and storage on lymphocyte subpopulations. Lancet (1983) 0.86
Immunoglobulins and antinuclear antibodies in aqueous humour from patients with juvenile "rheumatoid" arthritis (Still's disease). Trans Ophthalmol Soc U K (1977) 0.86
Recurrent malignant melanoma of the corneal stroma: a case of 'black cornea'. Br J Ophthalmol (1992) 0.85
Prophylactic retinal radiotherapy has an exceptional place in the management of familial retinoblastoma. Br J Cancer (1993) 0.85
Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology (2001) 0.85
Autoimmunity and the outer retina. Trans Ophthalmol Soc U K (1983) 0.85
Lymphoproliferative disorders of the orbit: an immunological approach to diagnosis and pathogenesis. Br J Ophthalmol (1983) 0.85
Amine boranes as alternative reducing agents for reductive alkylation of proteins. Anal Biochem (1982) 0.84
Effects of alkali on proteins. Disulfides and their products. J Agric Food Chem (1977) 0.84
Prognsotic parameters in choroidal melanomata. Trans Ophthalmol Soc U K (1977) 0.84
Uveal melanoma: is solar ultraviolet radiation a risk factor? Ophthalmic Epidemiol (1994) 0.83
Pigmentation of the eyelid margin accompanying conjunctival melanoma. Am J Ophthalmol (1989) 0.83
Retinoblastoma in association with the chromosome breakage syndromes Fanconi's anaemia and Bloom's syndrome: clinical and cytogenetic findings. Clin Genet (1995) 0.83
Treatment of retinoblastoma vitreous base seeding. Ophthalmology (1998) 0.83
Immunoglobulin A (IgA) deficiency and eye disease. Trans Ophthalmol Soc U K (1981) 0.83
Lymphoproliferative response as an index of cellular immunity in malignant melanoma of the uvea and its correlation with the histological features of the tumour. Br J Ophthalmol (1980) 0.83
Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer (1995) 0.83
HLA and eye disease. Br J Ophthalmol (1979) 0.83
Tumours of the anterior uvea. II. Intranuclear cytoplasmic inclusions in malignant melanoma of the iris. Br J Ophthalmol (1980) 0.82